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Identification and delineation of tumor burden on MR images is a critical, yet 
challenging, function for clinical care and neuro-oncology research. Changes in tumor burden on 
structural MRI sequences are used as surrogates for efficacy throughout the entire drug 
development pipeline, from initial preclinical evaluations through clinical t   human 
patients. DeepNeuro, the algorithm recently published by Chang et al.1     utomated 
approaches to tumor segmentation (see reviews by Gordillo et al.2    l.3, and Bauer et 
al.4), combined with standardization of image acquisition and g ble interpretation of 
radiographic changes, holds great promise for accurate, re e, efficient, and inexpensive 
tumor segmentation.  
Manual or semi-automated quant   r size by experts using commercial or 
academic tools is highly variable acros  5 and is extremely time consuming, labor 
intensive, inefficient, and expen  ert neuroradiologists in large clinical trials average 
more than 40% adjudicati   which is consistent with adjudication or discrepancy rates 
between radiologists in  or types and between central review compared with local site 
call of progression  Difficulty in determining changes in T2 hyperintense lesions on 
RANO was o  ermined to be the largest reason for adjudication, while changes in contrast 
en  eared less ambiguous, but still relatively difficult. While some investigators 
h  ed volumetric segmentation on T1 subtraction maps may be a way to replace 
blinded, adjudicated central reads10, there remains significant questions as to the reproducibility 
of simple segmentation approaches in the presence of artifacts and generalization of these 
threshold-based segmentation techniques for all relevant components of the tumor (e.g. 
enhancing, necrotic, and non-enhancing disease). Automated segmentation and quantitative 
  
 
response assessment using a large set of post-therapeutic data, as demonstrated by DeepNeuro1, 
has significant potential to reduce these adjudication rates while allowing investigators and 
regulators to evaluate potential changes in various aspects of the tumor biology. 
In addition to standard response assessment, clearly defining regions of interest for both 
T2 hyperintense lesions (e.g. edema and/or non-enhancing tumor) and contrast en  lesions 
on post-contrast T1-weighted images are critical for obtaining advanced im  urements 
(diffusion, perfusion, PET, etc.) within areas of active disease. Thu   gmentation itself 
adds another level of uncertainty beyond the inherent variabilit   d image acquisition 
and post-processing. The use of an automated and standar  umor segmentation algorithm 
like DeepNeuro could conceivably reduce variabilit  i  ced imaging analyses and increase 
repeatability of results across centers and   
Performance of sophisticated alg  e DeepNeuro are going to greatly improve 
through the adaptation and impl n of the standardized brain tumor imaging protocol 
(BTIP)11. Introduced in 2015   sult of a joint meeting between the FDA, NCI, clinical 
scientists, imaging exp  maceutical and biotech companies, clinical trial cooperative 
groups, and patie   oups, BTIP is compliant with ACRIN and EORTC guidelines 
and includes  mum recommended sequences for response assessment using 1.5T and 3T 
M   ince most machine learning algorithms utilize public datasets obtained from 
in  stitutions or trials that may not be BTIP compliant, they are innately designed to 
generalize across a wide range of acquisition parameters and machine settings. By streamlining 
and focusing the range of MR parameters that are acceptable for use in clinical trials, 
performance of automated algorithms will theoretically improve as trials comply with BTIP and 




“ We are drowning in data but starved for wisdom.”  
~ Arianna Huffington, Founder of Huffington Post re: Artificial Intelligence 
More than 200 scientific abstracts, plenary talks, and presentations were devoted to 
artificial intelligence or machine learning at the 2018 Radiologic Society of  America 
(RSNA) annual meeting last year. In radiology, artificial i
approaches are changing the way we schedule patients, acquire  -process images, 
measure tumor size, dictate or interpret changes, and charge  g cal services. While 
DeepNeuro and other techniques with automatic pipelines  omise of reducing ambiguity 
and variability in tumor segmentation, these alg ith   , 
which may be problematic as experts ma    y vetted or trained, may have difficulty 
accurately defining tumor boundaries   gliomas, and/or they may not utilize all 
approaches we know to be usefu   ning active disease (e.g. T1 subtraction maps, subtle 
signal intensity changes on T2 ed images, architectural disruption at the gray-white matter 
boundary, etc.). Addit  ost of the available automated algorithms have been trained 
entirely on treatm   ors5, which is a much simpler problem (i.e. no post-surgical or 
post-therapeu  ges) with no tangible clinical impact. It is more meaningful, and admittedly 
m    try and differentiate changes in tumor during the post-therapeutic setting or 
d  ment with experimental therapeutics. While DeepNeuro may not have not yet 
undergone extensive testing under various therapeutic contexts (e.g. anti-angiogenic or 
immunotherapies), or in challenging tumor types (e.g. gliomatosis cerebri, mixed grade tumors, 
etc.), their attempt to adapt their algorithm to perform an automated response assessment during 
treatment within a clinical trial is a strong, noteworthy step in the right direction. Thus, while 
  
 
promising, artificial intelligence is inherently only as good as the knowledge we are able to 
provide. These algorithms currently cannot generate new wisdom into the intrinsic biology of 
brain tumors, nor can they begin to unravel the true extent of tumor infiltration into the brain. 
Perhaps someday, with the addition of autopsy data, this later goal could become a reality. 
However, just like humans, these new A.I. algorithms have the ability to adapt  ad  arn, and 
-  based on new or improved knowledg   
We are at the dawn of a renaissance in imaging technology i  cology. Artificial 
intelligence-based techniques and approaches for automated re  ssment are going to 
increase in sophistication and complexity in the years and s to come. Investigators and 
regulators should be acutely aware of the limitati    echnology, providing wisdom and 
context to further guide the developmen   ation in both clinical trials and clinical 








1. Chang K, Beers AL, Bai HX, et al. Automatic assessment of glioma burden: A deep 
learning algorithm for fully automated volumetric and bi-dimensional measurement. 
Neuro Oncol. 2019. doi.org/10.1093/neuonc/noz106 
2. Gordillo N, Montseny E, Sobrevilla P. State of the art survey on MRI brain tumor 
segmentation. Magn Reson Imaging. 2013; 31(8):1426-1438. 
3. -based Brain Tumor Image Se tion 
Using Deep Learning Methods,. Procedia Computer Science. 2016; 102:3  
4. Bauer S, Wiest R, Nolte LP, Reyes M. A survey of MRI-based medical  lysis 
for brain tumor studies. Phys Med Biol. 2013; 58(13):R97-129. 
5. Menze BH, Jakab A, Bauer S, et al. The Multimodal Brain Tumor  ntation 
Benchmark (BRATS). IEEE Trans Med Imaging. 2015; 34(10 24. 
6. 
in blinded independent central review of oncology studie    ls. 2016; 6(5):289. 
7. Boxerman JL, Zhang Z, Safriel Y, et al. Early post-b  progression on contrast-
enhanced MRI as a prognostic marker for overall sur   recurrent glioblastoma: 
results from the ACRIN 6677/RTOG 0625 Cen   tudy. Neuro Oncol. 2013; 
15(7):945-954. 
8. Pope WB, Hessel C. Response assessment  oncology criteria: implementation 
challenges in multicenter neuro-on   JNR Am J Neuroradiol. 2011; 
32(5):794-797. 
9. Dodd LE, Korn EL, Freidlin B, et   independent central review of progression-
free survival in phase III c   p tant design element or unnecessary 
expense? J Clin Oncol. 20  ):3791-3796. 
10. Schmainda KM, Prah M   , et al. Quantitative Delta T1 (dT1) as a Replacement 
for Adjudicated Ce   Analysis of Contrast-Enhancing Tumor Burden: A 
Subanalysis of the  ollege of Radiology Imaging Network 6677/Radiation 
Therapy Oncolo   0625 Multicenter Brain Tumor Trial. AJNR Am J Neuroradiol. 
2019; 40(7):113  
11. Ellingson B   M, Boxerman J, et al. Consensus recommendations for a 
standa   Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015; 
17(9): 98. 
 
